Emanuele Di Martino

Emanuele Di Martino

Auto-generated profile, based on publicly available information

Emanuele Di Martino

University of Pisa, Pisa, Italy

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2014 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
Martina LombardiMartina Lombardi
Martina Lombardi
ILI. Lupi
I. Lupi
MCMirco Cosottini
Mirco Cosottini
GRGian Paolo Rossi
Gian Paolo Rossi
LML. Manetti
L. Manetti
FBF. Bogazzi
F. Bogazzi
Dopamine agonists are considered as the first line therapy in prolactin (PRL) secreting pituitary adenomas inducing a normalization of serum PRL and reduction of tumor size. It is known that serum PRL levels, obtained during treatment, are a predictor of tumor shrinkage. Whether PRL suppression below the lower limit of the normal range is related to a greater chance of tumor shrinkage than just its normalization has not been established. This retrospective cohort study was carried out in a tertiary center. Clinical records of 151 patients with PRL-secreting pituitary adenomas (73 micro-, 78 macroadenomas) treated with cabergoline for at least 24 months were analyzed. The adenoma size was analyzed by MRI before and after 24 months of treatment. PRL levels were evaluated every 6 months, assigning a score at each time point (PRL 0=suppressed; 1=normal; 2=above normal). The total score, after 24 months of treatment, was expressed as the sum of the score at each time point and ranged between 0 and 8. A tumor shrinkage was observed in 102/151 patients (67.5%) and it was significantly associated to a lower PRL total score (p=0.021, OR=0.85, CI=0.73–0.97), being significantly more frequent in patients with suppressed PRL than in those with normal PRL (p=0.045, OR=0.42, CI=0.18–0.98) at 24 months. Cabergoline therapy with the goal of achieving PRL levels below the lower limit of normal range can increase the chance to obtain tumor shrinkage of PRL-secreting pituitary adenomas.

25 April 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FGFrancesca Guida
Francesca Guida
MIMonica Iannotta
Monica Iannotta
MPMichela Perrone
Michela Perrone
RIRosmara Infantino
Rosmara Infantino
GGGiada Giorgini
Giada Giorgini
SMSabatino Maione
Sabatino Maione
There is a growing evidence suggesting the association of vitamin D deficiency (VDD) and cognitive impairment. In this study we evaluated the possible involvement of gut microbiota in the cognitive impairments mediated by VDD and investigated the effects of pharmacological treatment with the oxazoline derivative of the aliamide palmitoylethanolamide, 2-Pentadecyl-2-oxazoline (PEA-OXA). Mice were submitted to behavioural, biochemical and electrophysiological analysis to assess whether their vitamin D status affected cognitive performance together with gut microbiota composition. In VDD mice we found cognitive malfunctioning associated with reduced neuroplasticity, indicated by impaired long term potentiation, and neuroinflammation at the hippocampal level. Importantly, PEA-OXA counteracted the cognitive impairments and modified the biochemical and functional changes induced by VDD. Additionally, PEA-OXA treatment enhanced gut microbiota diversity, which tended to be decreased by VDD only in female mice, elevated the relative abundance of lactic and butyric acidproducing families, i.e. Aerococcaceae and Butyricicoccaceae, and reversed the VDD-induced decrease of butyrateproducing beneficial genera, such as Blautia in female mice, and Roseburia in male mice. These data provide novel insights for a better understanding of the cognitive decline induced by VDD and related gut dysbiosis and its potential therapeutic treatment.

4 April 1992 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
LGL. Grasso
L. Grasso
PMP. L. Maxia
P. L. Maxia
LBLuigi Bartalena
Luigi Bartalena
MMMichele Murtas
Michele Murtas
ATA. Taberlet
A. Taberlet
EME. Martino
E. Martino

1 August 2020 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
FTF. Trimarchi
F. Trimarchi
EME. Martino
E. Martino
LBLuigi Bartalena
Luigi Bartalena

27 July 2017 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
EME. Martino
E. Martino

25 April 2017 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
EMEnio Martino
Enio Martino